References
- Ritterhoff J, Most P. Targeting S100A1 in heart failure. Gene Ther. 2012 Jun;19(6):613–621. doi: 10.1038/gt.2012.8
- Rohde D, Busch M, Volkert A, et al. Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1‘s triple action in cardiovascular pathophysiology. Future Cardiol. 2015 May;11(3):309–321.
- Heizmann CW, Fritz G, Schäfer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002 May 1;7(4):d1356–1368. doi: 10.2741/A846
- Remppis A, Greten T, Schäfer BW, et al. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta. 1996 Oct 11;1313(3):253–257. doi: 10.1016/0167-4889(96)00097-3
- Zimmer DB, Song W, Zimmer WE. Isolation of a rat S100 alpha cDNA and distribution of its mRNA in rat tissues. Brain Res Bull. 1991 Aug;27(2):157–162. doi: 10.1016/0361-9230(91)90061-N
- Pleger ST, Harris DM, Shan C, et al. Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res. 2008 Apr 11;102(7):786–794. doi: 10.1161/CIRCRESAHA.108.172031
- Rohde D, Schön C, Boerries M, et al. S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4. EMBO Mol Med. 2014 Jun;6(6):778–794.
- Most P, Pleger ST, Volkers M, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004 Dec;114(11):1550–1563.
- Kiewitz R, Acklin C, Schafer BW, et al. Ca2+ -dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+ -ATPase2a and phospholamban in the human heart. Biochem Biophys Res Commun. 2003 Jun 27;306(2):550–557. doi: 10.1016/S0006-291X(03)00987-2
- Most P, Seifert H, Gao E, et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation. 2006 Sep 19;114(12):1258–1268. doi: 10.1161/CIRCULATIONAHA.106.622415
- Ritterhoff J, Volkers M, Seitz A, et al. S100A1 DNA-based inotropic therapy protects against proarrhythmogenic ryanodine receptor 2 dysfunction. Mol Ther. 2015 Aug;23(8):1320–1330.
- Yamasaki R, Berri M, Wu Y, et al. Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1. Biophys J. 2001 Oct;81(4):2297–2313.
- Boerries M, Most P, Gledhill JR, et al. Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol. 2007 Jun;27(12):4365–4373.
- Most P, Lerchenmüller C, Rengo G, et al. S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation. Circ Res. 2013 Jan 4;112(1):66–78. doi: 10.1161/CIRCRESAHA.112.275156
- Brinks H, Rohde D, Voelkers M, et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol. 2011 Aug 23;58(9):966–973. doi: 10.1016/j.jacc.2011.03.054
- Pleger ST, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med. 2011 Jul 20;3(92):92ra64. doi: 10.1126/scitranslmed.3002097
- Pleger ST, Most P, Boucher M, et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007 May 15;115(19):2506–2515. doi: 10.1161/CIRCULATIONAHA.106.671701
- Remppis A, Pleger ST, Most P, et al. S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med. 2004 Apr;6(4):387–394.
- Kehr D, Ritterhoff J, Glaser M, et al. S100A1ct: a synthetic peptide derived from human S100A1 protein improves cardiac contractile performance and survival in pre-clinical heart failure models. bioRxiv. 2023; 2023–03.